Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine/busulfan

Autor: Shimoni, A.¹ ashimoni@sheba.health.gov.il, Hardan, I.¹, Shem-Tov, N.¹, Rand, A.¹, Herscovici, C.¹, Yerushalmi, R.¹, Nagler, A.¹

Publikováno v: Leukemia (08876924). Oct2007, Vol. 21 Issue 10, p2109-2116. 8p. 5 Charts, 4 Graphs.

Adjuvant treatment of high-risk stage II breast cancer with doxorubicin followed by high-dose chemotherapy and autologous stem-cell transplantation: a single-institution experience with 132 consecutive patients.

Autor: Stemmer, S M, Hardan, I, Raz, H, Adamou, A K, Inbar, M, Gottfried, M, Merrick, Y, Cohen, Y, Sulkes, A, Ben-Baruch, N, Pfeffer, R P, Brenner, H J, Rizel, S

Publikováno v: Bone Marrow Transplantation. Apr2003, Vol. 31 Issue 8, p655. 7p.

Continuous therapy versus fixed duration of therapy in patients with newly diagnosed multiple myeloma

Autor: Palumbo, A. Gay, F. Cavallo, F. Raimondo, F.D. Larocca, A. Hardan, I. Nagler, A. Petrucci, M.T. Hajek, R. Pezzatti, S. Delforge, M. Patriarca, F. Donato, F. Cerrato, C. Nozzoli, C. Yu, Z. Boccadifuoco, L. Caravita, T. Benevolo, G. Guglielmelli, T. Vincelli, D. Jacques, C. Dimopoulos, M.A. Ciccone, G. Musto, P. Corradini, P. Cavo, M. Boccadoro, M.

Purpose: Continuous therapy (CT) prolongs progression-free survival 1 (PFS1; time from random assignment until the first progression or death), but chemotherapy-resistant relapse may negatively impact overall survival (OS). Progression-free survival

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::84c5fc1fe638214b14ebacf82d99e242
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3087647

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib:A multicenter international myeloma working group study

Autor: Kumar S. K., Lee J. H., Lahuerta J. J., Morgan G., Richardson P. G., Crowley J., Haessler J., Feather J., Hoering A., Moreau P., LeLeu X., Hulin C., Klein S. K., Sonneveld P., Siegel D., Bladé J., Goldschmidt H., Jagannath S., Miguel J. S., Orlowski R., Palumbo A., Sezer O., Rajkumar S. V., Durie B. G. International Myeloma Working Group Abildgaard N, Abonour R, Alexanian R, Alsina M, Anderson KC, Attal M, Avet Loiseau H, Badros A, Baris D, Barlogie B, Bataille R, Beksaç M, Belch A, Ben Yehuda D, Bensinger B, Bergsagel PL, Bird J, Bladé J, Boccadoro M, Chanan Khan A, Chen WM, Child T, Chim J, Chng WJ, Comenzo R, Crowley J, Dalton W, Davies F, de Souza C, Delforge M, Dimopoulos M, Dispenzieri A, Drach J, Drake M, Durie BG, Einsele H, Facon T, Fantl D, Fermand JP, Fonseca R, Gahrton G, García Sanz R, Gasparetto C, Gertz M, Gibson J, Giralt S, Goldschmidt H, Greipp P, Hajek R, Hardan I, Hari P, Harousseau JL, Hata H, Hattori Y, Heffner T, Ho J, Hungria V, Ida S, Jacobs P, Jagannath S, Johnsen HE, Jian H, Joshua D, Jurczyszyn A, Kawano M, Kröger N, Kumar S, Kyle RA, Lacy M, Lahuerta JJ, Landgren O, Laubach J, Lee JH, LeLeu X, Lentzsch S, Lokhorst H, Lonial S, Ludwig H, Maiolino A, Mateos M, Mehta J, Mellqvist UH, Merlini G, Mikhael J, Morales AR, Moreau P, Morgan G, Nahi H, Munshi N, Niesvizky R, Nouel A, Novis Y, Orlowski R, Palumbo A, Pavlovsky S, Pilarski L, Powles R, Raje N, Rajkumar SV, Reece D, Reiman T, Richardson PG, Roodman D, Rosiñol L, San Miguel J, Sezer O, Shah JJ, Shaughnessy J, Shimizu K, Shustik C, Siegel D, Singhal S, Sonneveld P, Spencer A, Stadtmauer E, Stewart K, Terpos E, Tosi P, Tricot G, Turesson I, Van Camp B, Van Ness B, Van Riet I, Vande Broek I, Vanderkerken K, Vescio R, Vesole D, Waage A, Wang M, Weber D, Westin J, Wheatley K, Zonder J., CAVO, MICHELE

Publikováno v: Kumar, S K, Lee, J H, Lahuerta, J J, Morgan, G, Richardson, P G, Crowley, J, Haessler, J, Feather, J, Hoering, A, Moreau, P, Leleu, X, Hulin, C, Klein, S K, Sonneveld, P, Siegel, D, Bladé, J, Goldschmidt, H, Jagannath, S, Miguel, J S, Orlowski, R, Palumbo, A, Sezer, O, Rajkumar, S V, Durie, B G M, Abildgaard, N, Abonour, R, Alexanian, R, Alsina, M, Anderson, K C, Attal, M, Avet-Loiseau, H, Badros, A, Baris, D, Barlogie, B, Bataille, R, Beksaç, M, Belch, A, Ben-Yehuda, D, Bensinger, B, Leif Bergsagel, P, Bird, J, Bladé, J, Boccadoro, M, Cavo, M, Chanan-Khan, A, Ming Chen, W, Child, T, Chim, J, Chng, W-J, Johnsen, H & on behalf of the International Myeloma Working Group 2012, ' Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib : A multicenter international myeloma working group study ', Leukemia, vol. 26, no. 1, pp. 149-57 . https://doi.org/10.1038/leu.2011.196
Kumar, S K, Lee, JH, Lahuerta, J J, Morgan, G, Richardson, P G, Crowley, J, Haessler, J, Feather, J, Hoering, A, Moreau, P, LeLeu, X, Hulin, C, Klein, S K, Sonneveld, P, Siegel, D, Bladé, J, Goldschmidt, H, Jagannath, S, Miguel, J S, Orlowski, R, Palumbo, A, Sezer, O, Rajkumar, S V, Durie, B G M, International Myeloma Working Group & Abildgaard, N 2012, ' Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib : a multicenter international myeloma working group study ', Leukemia, vol. 26, no. 1, pp. 149-57 . https://doi.org/10.1038/leu.2011.196
Leukemia, 26(1), 149-157. Nature Publishing Group

Promising new drugs are being evaluated for treatment of multiple myeloma (MM), but their impact should be measured against the expected outcome in patients failing current therapies. However, the natural history of relapsed disease in the current er

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2dbe6ffe8c2635e6295f17f425b101c
https://pure.au.dk/portal/da/publications/risk-of-progression-and-survival-in-multiple-myeloma-relapsing-after-therapy-with-imids-and-bortezomib(9b065552-2900-4784-9cd2-fd53f87d51ac).html

Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: long-term follow-up.

Autor: Shimoni, A.¹ ashimoni@sheba.health.gov.il, Hardan, I.¹, Shem-Tov, N.¹, Yerushalmi, R.¹, Nagler, A.¹

Publikováno v: Leukemia (08876924). May2010, Vol. 24 Issue 5, p1050-1052. 3p. 2 Graphs.